FIELD: medicine; pharmaceutics.
SUBSTANCE: invention relates to a composition for use in treating an eye disease, wherein the composition contains a pharmaceutically acceptable carrier and a pharmaceutically acceptable salt of a compound of formula (I), where R1-R9, p are defined in the claim, and at least 90% of the compound in the composition is present in the form of a salt.
EFFECT: when injected into the eye, the peptide compositions described herein increase the amount of lachrymal secretion and promote repair of the injured cornea.
21 cl, 68 dwg, 8 tbl, 5 ex
| Title | Year | Author | Number |
|---|---|---|---|
| NEW PEPTIDE AND PHARMACEUTICAL COMPOSITION FOR TREATMENT OF EYE DISEASE, CONTAINING PEPTIDE AS ACTIVE PHARMACEUTICAL INGREDIENT | 2018 |
|
RU2766160C2 |
| METHODS, COMPOSITIONS AND IMPLANTED ELEMENTS CONTAINING ACTIVE CELLS | 2018 |
|
RU2826206C2 |
| COMPOSITIONS FOR TREATING CANCER USING ANTAGONISTS WHICH BIND TO THE PD-1 SIGNALING PATHWAY COMPONENT AND MEK INHIBITORS | 2015 |
|
RU2733735C2 |
| COMPOSITIONS AND METHODS RELATING TO DRUG CONJUGATES WITH ANTI-CD19 ANTIBODIES | 2019 |
|
RU2806333C2 |
| CONJUGATES OF ENGINEERED ANTIBODIES WITH CYSTEINE SUBSTITUTES | 2016 |
|
RU2733740C2 |
| ANTI-FcRH5 ANTIBODIES | 2014 |
|
RU2687132C2 |
| ANTIANGIOGENIC COMPOUNDS | 2009 |
|
RU2511420C2 |
| HYDANTOIN MODIFIED MELANOCORTIN RECEPTOR LIGANDS | 2008 |
|
RU2450017C2 |
| HUMAN EZH2 INHIBITORS AND METHODS FOR USE THEREOF | 2013 |
|
RU2704445C2 |
| ANTI-CD22 ANTIBODY-MAITANSIN CONJUGATES AND METHODS OF THEIR APPLICATION | 2016 |
|
RU2744895C2 |
